Citius Oncology Inc. Common Stock (CTOR)
Stock · NASDAQ · Health Care
$0.768as of 10/16/2026
Price chart
Active signals
CTOR Signal Track Record
How signals performed across all stocks →What CTOR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 25 | -0.9% | 48% | September 29, 2026 |
| Bollinger Band Breakout | 18 | +0.1% | 50% | September 8, 2026 |
| Bollinger Band Breakdown | 8 | -13.2% | 38% | July 20, 2026 |
| Any 20-session window (baseline) | +0.3% | 55% |
Computed by MarketWall from daily closing prices since September 26, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CTOR
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Bio…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- citiusonc.com/
Fundamentals
- 1-day range
- $0.7451$0.7699
- Market cap
- $70.67M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.48
- Dividend yield
- —
- Beta
- 3.36
- Avg. volume
- 102.8K
Forecasts
1 analyst ratings
Citius Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CTORCitius Oncology Inc. Common Stock$0.768▲ 2.95%Market cap $70.67MP/E —$0.491$2.25
- INOInovio Pharmaceuticals Inc. Common Stock$0.99▼ 4.81%Market cap $69.62MP/E —$0.5632$2.72
- CYPHCypherpunk Technologies Inc. Common Stock$2.57▼ 14.90%Market cap $71.74MP/E —$0.393$4.19
- XBITXBiotech Inc. Common Stock$2.12▼ 1.85%Market cap $69.51MP/E —$2.09$3.44
- IBIOiBio Inc. Common Stock$0.77▼ 1.28%Market cap $69.05MP/E —$0.7328$3.82
- ELTXElicio Therapeutics Inc. Common Stock$1.56▼ 12.36%Market cap $72.28MP/E —$1.71$16
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTOR Citius Oncology Inc. Common Stock | $70.67M | — | $0.768 | ▲ 2.95% | $0.491$2.25 |
| INO Inovio Pharmaceuticals Inc. Common Stock | $69.62M | — | $0.99 | ▼ 4.81% | $0.5632$2.72 |
| CYPH Cypherpunk Technologies Inc. Common Stock | $71.74M | — | $2.57 | ▼ 14.90% | $0.393$4.19 |
| XBIT XBiotech Inc. Common Stock | $69.51M | — | $2.12 | ▼ 1.85% | $2.09$3.44 |
| IBIO iBio Inc. Common Stock | $69.05M | — | $0.77 | ▼ 1.28% | $0.7328$3.82 |
| ELTX Elicio Therapeutics Inc. Common Stock | $72.28M | — | $1.56 | ▼ 12.36% | $1.71$16 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/18/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 14.13M
- Total value held
- $8.75M
- Institutional holders
- 13
- Unknown9.19M
- Unknown3.84M
- Unknown534.8K
- Unknown264.7K
- Unknown107.4K
- Unknown47.5K
- Unknown45.7K
- Unknown42.9K
- Unknown36.8K
- Unknown11.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
CTOR to Join October 2026 Investor Conferences
Citius Oncology announced it will take part in investor conferences scheduled for October 2026. The events give the company a platform to present its pipeline and business updates to potential investors. The stock is currently trading near its long‑term support level, which may be observed by attendees.
CTOR to Join October 2026 Investor Conferences. Citius Oncology announced it will take part in investor conferences scheduled for October 2026. The events give the company a platform to present its pipeline and business updates to potential investors. The stock is currently trading near its long‑term support level, which may be observed by attendees.